TREACE MEDICAL CONCEPTS, INC. (TMCI): M&A transaction — Treace Medical completes $20M acquisition of RedPoint Medical3D's PSI assets

TREACE MEDICAL CONCEPTS, INC.

Paid $20M cash at closing for RPM-3D assets used in pre-op planning and patient-specific guides for bunion surgery.
Earnout up to $10M: $3.5M for transition services, $3.5M for tech milestones, up to $3M upon patent issuance.
RPM-3D software integration with Lapiplasty system planned for 2023; commercial launch expected H2 2024.
CEO says acquisition adds FDA-cleared PSI technologies, expanding customization for Lapiplasty and Adductoplasty.
Entered non-compete/non-solicitation agreements with RPM-3D and consulting agreements with Dr. Adam Perler and James Spitler.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

TREACE MEDICAL CONCEPTS, INC. completed an acquisition involving MIOS Marketing, LLC d/b/a RedPoint Medical3d ("RPM-3D") for $20.0 million (closed 2023-06-12).

Action: acquisition
Counterparty: MIOS Marketing, LLC d/b/a RedPoint Medical3d ("RPM-3D")
Consideration: $20.0 million
Closing: 2023-06-12

Exact text from the filing

of RPM-3D. On June 12, 2023, the Company completed its acquisition of certain assets of RPM-3D pursuant to the APA. In accordance with the APA, at closing, TMCI paid RPM-3D $20.0 million in exchange for RPM-3D’s assets used in providing pre-operative planning and patient-specific guides for the surgical correction of foot and ankle deformities. Under the APA,

View on SEC.gov

Browse all m&a transactions →

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-027758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.